Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 4/20 | 0.36 |
| ▸ | HTR1D | P28221 | 4/20 | 0.36 |
| ▸ | HTR1B | P28222 | 4/20 | 0.36 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13106641 | 0.91 | GPBAR1 (0.36) | MAPTMAOBHTR6HTR1AABCG2 | |
| SCHEMBL13097298 | 0.90 | CYP2D6 (0.38) | MAPTMAOBHTR6F10HTR1A | |
| SCHEMBL13097290 | 0.89 | F10 (0.37) | MAPTMAOBHTR6F10HTR1A | |
| SCHEMBL13097314 | 0.86 | MAOB (0.44) | MAPTMAOBHTR6F10HTR1A | |
| SCHEMBL13097067 | 0.85 | MAOB (0.47) | MAPTMAOBF10 | |
| SCHEMBL13097081 | 0.84 | MAPT (0.43) | MAPTHTR1AHTR1DHTR1BABL1 | |
| SCHEMBL13097085 | 0.82 | PRKDC (0.44) | MAPTHTR1AHTR1DHTR1B | |
| SCHEMBL13106618 | 0.81 | CYP2D6 (0.37) | MAPTMAOBHTR6ABCG2 | |
| SCHEMBL13097318 | 0.80 | PRMT5 (0.44) | MAPTF10ABCG2MGLLHRH4 | |
| SCHEMBL13106690 | 0.80 | DHODH (0.35) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | MAPT 4661/4885MAOB 200/4885HTR6 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.